more

DexCom (DXCM)

(Delayed Data from NSDQ)

$72.24 USD

-1.43 (-1.94%)

Updated Aug 27, 2024 03:59 PM ET

After-Market: $72.22 -0.02 (-0.03%) 6:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

Top 29% (72 out of 251)

Industry: Medical - Instruments

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

DexCom (DXCM) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research Published on November 01,2019

DexCom's (DXCM) Q3 earnings is likely to reflect top-line growth and rising global awareness of the company's real-time CGM.

DexCom's (DXCM) New G6 Pro CGM System Gets FDA Approval

by Zacks Equity Research Published on October 09,2019

FDA approval for DexCom's (DXCM) G6 Pro boosts the company's broad product spectrum.

medical

Stocks & ETF to Invest in Healthcare Robotics and Innovation

by Neena Mishra Published on September 27,2019

HTEC is poised to benefit from rapid advances in health-care technology

etfs
medical

Stocks & ETF to Invest in Healthcare Robotics and Innovation

by Neena Mishra Published on September 23,2019

HTEC is poised to benefit from rapid advances in health-care technology.

CGM Devices Gain Steam, Set New Trend in Diabetes Management

by Urmimala Biswas Published on September 20,2019

The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.

medical

IoMT Becomes the Buzzword in New Age MedTech Investing

by Urmimala Biswas Published on September 13,2019

Increasing adoption of cloud platforms, phones, phablets, tablets and other smart devices as well as apps is making acceptance of IoMT easier among the masses.

Here's Why You Should Hold on to DexCom (DXCM) Stock Now

by Zacks Equity Research Published on September 03,2019

DexCom (DXCM) continues to benefit from growing glucose monitoring market, strategic buyouts and strong international presence. However, margin contraction remains a woe.

medical

DexCom (DXCM) Scales 52-Week High: What's Driving the Stock?

by Zacks Equity Research Published on August 29,2019

DexCom (DXCM) has various favorable factors to maintain the current high.

medical

DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research Published on August 02,2019

Higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook benefit DexCom's (DXCM) Q2 earnings. However, contraction in gross margin remains a woe.

DexCom (DXCM) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research Published on August 02,2019

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More

by Zacks Equity Research Published on July 30,2019

Solid growth in emerging markets is expected to be an added positive this earnings season.

What's in the Offing for DexCom's (DXCM) Earnings in Q2?

by Zacks Equity Research Published on July 25,2019

Top-line growth and rising global awareness of the company's real-time CGM are likely to aid DexCom's (DXCM) Q2 earnings.

DexCom (DXCM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research Published on July 24,2019

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DXCMNegative Net Change

3 Internet of Things Stocks to Buy for July

by Benjamin Rains Published on July 12,2019

Today we've highlighted three, Zacks buy-ranked stocks with growing IoT businesses that investors might want to consider at the moment...

All You Need to Know About DexCom (DXCM) Rating Upgrade to Strong Buy

by Zacks Equity Research Published on July 11,2019

DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

DXCMNegative Net Change

Profit from Surprise in Q2 2019 Earnings Season

by Benjamin Rains Published on July 09,2019

Second quarter 2019 earnings season unofficially starts early next week when the big banks report. So let's take a look at some stocks that could shine for investors...

Will MedTech Ease Investors' Concern & Outperform? 4 Picks

by Urmimala Biswas Published on July 05,2019

Lower investment in MedTech might prove to be a concern, more so as gains within this space are staggering.

ETF & Stock Winners of Longest US Economic Expansion

by Sanghamitra Saha Published on July 03,2019

The U.S. economy has stepped into the 11th year of the expansion, exhibiting the longest expansion in history. These winning ETFs and stocks will rally further.